Daily Roundup

Netwealth Group has been served with a class action claim related to First Guardian investment options offered through its Superannuation Master Fund. The company's subsidiaries, Netwealth Investments Limited and Netwealth Superannuation Services Pty Ltd, are named in the claim, which connects to issues previously addressed through a court-enforceable undertaking with ASIC. Netwealth completed a compensation program in January 2026 that paid approximately $101 million to affected members. The company has signaled its intention to defend the claim vigorously.

Healius has struck a deal to sell Agilex Biolabs, its wholly owned subsidiary, to Novotech Health Holdings for an enterprise value of A$160 million. The transaction is expected to deliver roughly $155 million in cash proceeds and should wrap up during the second half of FY 2027, pending standard conditions. The sale will allow Healius to sharpen its focus on its core Pathology business while unlocking value for shareholders. Notably, the company doesn't anticipate any tax liability from the transaction.

Over at Microba Life Sciences, there's been a leadership change. Chief Executive Officer Dr. Luke Reid is taking medical leave, prompting the board to appoint Geoffrey Cockerill as Interim CEO, effective 29 September 2026. Cockerill brings more than 30 years of executive experience, having held senior roles at Diageo Australia, Lion, and Subway Systems across Australia, New Zealand, and South-East Asia. He's also previously led Vitura Health Limited and ATP Science through transformation and growth initiatives. His interim appointment runs for an initial six months—extendable by mutual agreement—at a daily fee of $2,100 (excluding GST) for five days per week.

Matsa Resources has received a $10 million deposit from AngloGold Ashanti as part of a revised Tenement Option Agreement for specific tenements within Matsa's Lake Carey Gold Project near Laverton, Western Australia. The deposit follows AngloGold Ashanti's early exercise of the option and comes after Matsa secured ministerial consent, a key condition precedent. An additional $45 million remains payable once final completion conditions are met, including third-party consents and contractual access rights.

Memphasys has identified a potentially faster route into the US IVF market. The company's board reassessed its regulatory strategy and found a medical device that could serve as a predicate for the FDA's 510(k) clearance pathway—a more established route than the De Novo pathway previously considered. With the US IVF market valued at approximately $5.9 billion, Memphasys plans to engage with the FDA through a Pre-Submission process to gather feedback before submitting formally for its Felix device. The move could meaningfully accelerate the company's entry into a market served by over 500 clinics providing assisted reproductive technology services annually.